RxDoctor Payments Data

Harpaul Gill, MD

Hematology & Oncology · Alpharetta, GANPI 1386063964

Payments from drug & device makers

$192,864in general payments, 2019–2025

Across 365 payments — averaging $528.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$80K
  • Modernatx, Inc.$58K
  • E.r. Squibb & Sons, L.L.C.$39K
  • Pfizer$6K
  • Incyte Corporation$2K
  • CTI Biopharma Corp.$2K
  • plus $7K from 49 others

What the payments were for

  • Consulting fees$9,63051%
  • Speaking & faculty fees$1,7259%
  • Food & beverage$7,18938%
  • Education$2091%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$192,864 in reported general payments places this provider in the 80th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$126,880
Medicare patients
491
Services billed
1,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib30$501,970
BrukinsaZanubrutinib32$462,375
InlytaAxitinib24$390,514
Lenalidomide30$330,684
AlecensaAlectinib Hcl13$245,822
BraftoviEncorafenib15$229,905
TabrectaCapmatinib Hydrochloride12$201,323
MektoviBinimetinib15$200,282
LynparzaOlaparib13$199,132
ErleadaApalutamide15$186,092
XtandiEnzalutamide11$142,908
EliquisApixaban51$36,402
XareltoRivaroxaban20$18,898
Imatinib Mesylate36$10,708
Abiraterone Acetate12$6,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$12$501,97030 claims
Beigene USA, Inc.Brukinsa$130$462,37532 claims
Array Biopharma IncBraftovi, Mektovi$117$430,18730 claims
PfizerInlyta, Eliquis$6,238$426,91675 claims
Genentech USA, Inc.Alecensa$1,322$245,82213 claims
Johnson & JohnsonErleada, Xarelto$264$204,99035 claims
NovartisTabrecta$376$201,32312 claims
AstraZenecaLynparza$454$199,13213 claims
Astellas Pharma US IncXtandi$297$142,90811 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$14$6,75012 claims
Lilly USA, LLCOlanzapine$176$32030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →